Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was under development for renal cell carcinoma as first line therapy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

MARCH 22, 2023

Sandoz has more than two decades of experience researching, developing and bringing biosimilars to markets across the globe. 2 When it launches, Hyrimoz HCF will represent the first launch of a Sandoz biosimilar in the US market in this specific disease space. Head of North America.

FDA Approval 40

FDA Approval Generic Pharmaceutical Medicine Protein 40

The Pharma Data

OCTOBER 27, 2020

NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020 , after the market closes. Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Generic Pharmaceutical 52

Generic Pharmaceutical Packaging Packaging Manufacturing 52

Pharmaceutical Technology

DECEMBER 22, 2022

Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. The category includes any projects that demonstrate an innovative approach to the market.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

APRIL 4, 2023

With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

JUNE 8, 2022

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. As a result, the company is currently embroiled in legal disputes over claims of creating a market monopoly. percent.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69

The Pharma Data

JUNE 17, 2022

With a strong portfolio of eight marketed biosimilars and a further 15+ in various stages of development, Sandoz has an unparalleled heritage and extensive expertise in the development, manufacturing and delivery of biosimilar medicines to patients and the healthcare community worldwide.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

Pharma in Brief

SEPTEMBER 19, 2023

The Plaintiffs (Boehringer companies) allege that the Defendants (generic pharmaceutical companies) would infringe six Canadian patents if allowed to market generic empagliflozin products. In defence, the Defendants allege that the patents are invalid.

Regulation 52

Regulation Generic Pharmaceutical Compliance Medicine 52

The Pharma Data

OCTOBER 26, 2021

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines. Innovative Medicines net sales were USD 10.6 billion (+8%, +7% cc). percentage points (-3.6

Medicine 52

Medicine Sales Marketing Generic Pharmaceutical 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular injections.

Marketing 147

Marketing Generic Pharmaceutical Clinical Trials Clinical Trials 147

The Pharma Data

MARCH 15, 2022

“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D.,

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

Pharma in Brief

DECEMBER 3, 2023

The Regulations were meant to counterbalance the early-working exception by providing innovators with an enforcement tool to prevent patent infringement prior to generic or biosimilar market entry. Evolution of the Regulations Coming into force (1993–1997). Frequent amendments (1998–2016).

Regulation 52

Regulation Compliance Medicine Manufacturing 52

The Pharma Data

MAY 8, 2021

The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. About Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About Sandoz.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 15, 2023

Before joining EMMI Group as CEO, he was a Member of the Executive Board and Head of the Marketing Department at Migros-Genossenschafts-Bund. He holds a Master degree in Marketing and Trade from the University of St. Our ambition is to be the world’s leading and most valued generics company. Gallen (HSG), Switzerland.

Sales 40

Sales Production Doctors Doctor 40

The Pharma Data

MAY 18, 2021

By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive on the global market. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. About Sandoz.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

Pharmaceutical Technology

SEPTEMBER 23, 2022

For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.

Manufacturing 147

Manufacturing Drugs Production Packaging 147

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33

Sales 98

Sales Manufacturing FDA Approval Life Science 98

FDA Law Blog

JANUARY 24, 2024

If this vision is achieved, the United States can bring innovative biotechnologies and products to markets faster while building a more robust supply chain ecosystem. generic pharmaceutical industry, resulting in low profit-margins. The cost of implementing these technologies must be addressed.

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69

The Pharma Data

DECEMBER 23, 2020

COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

The Pharma Data

DECEMBER 23, 2020

. Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. The Company is marketing these products globally, in over 150 countries.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. It was a money-saving strategy that was paying off until Covid-19 hit. Please check your email to download the Report.

Production 263

Production Manufacturing Generic Drugs Drugs 263